Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization

Breast Cancer Research and Treatment

Volumn 82, Issue 2, 2003, Pages 125-141

  Guo, Baoqing ^a   Hembruff, Stacey L ^a   Villeneuve, David J ^a   Kirwan, Angie F ^a   Parissenti, Amadeo M ^a,b  

^a LAURENTIAN UNIVERSITY   (Canada)

^b Off of the Chair in Cancer Research   (Canada)

Author keywords

Apoptosis independent; Breast cancer; Calphostin C; Cytoplasmic vacuolization; Cytotoxicity; Drug resistance; P glycoprotein; PKC

Indexed keywords

CALPHOSTIN C; DOXORUBICIN; PACLITAXEL; PROPIDIUM IODIDE;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL LINE; CELL MEMBRANE; CELL VACUOLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MITOCHONDRION; MITOSIS; MULTINUCLEAR CELL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR GROWTH;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CASPASE 8; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROMES C; CYTOPLASM; DNA, NEOPLASM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; INHIBITORY CONCENTRATION 50; MICROSCOPY, FLUORESCENCE; NAPHTHALENES; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; VACUOLES;

EID: 0344825936     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000003969.21267.81     Document Type: Article

References (94)

1. Liu ZL, Onda K, Tanaka S, Toma T, Hirano T, Oka K: Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Cancer Chemother Pharmacol 49: 391-397, 2002
2. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002
3. Childs S, Ling V: The MDR superfamily of genes and its biological implications. Important Adv Oncol 21-36, 1994
4. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line [see comments]. Science 258: 1650-1654, 1992
5. Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nat Med 1: 578-582, 1995
6. Germann UA: P-glycoprotein-a mediator of multidrug resistance in tumor cells. Eur J Cancer 32A: 927-944, 1996
7. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA: Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91: 429-433, 1999
8. Tan B, Piwnica-Worms D, Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol 12: 450-458, 2000
9. Kerb R, Hoffmeyer S, Brinkmann U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2: 51-64, 2001
10. Fojo A, Akiyama S, Gottesman MM, Pastan I: Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 45: 3002-3007, 1985
11. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398, 1999
12. Shabbits J, Krishna R, Mayer L: Molecular and pharmacological strategies to overcome multidrug resistance. Expert Rev Anticancer Ther 1: 585-594, 2001
13. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N: Molecular targeting therapy of cancer: drug resistance apoptosis and survival signal. Cancer Sci 94: 15-21, 2003
14. Harris AL, Hochhauser D: Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31: 205-213, 1992
15. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, Hickson ID: Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51: 6592-6595, 1991
16. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G: Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52: 1666-1674, 1992
17. Elliott T, Sethi T: Integrins and extracellular matrix: a novel mechanism of multidrug resistance. Expert Rev Anticancer Ther 2: 449-459, 2002
18. Friesen C, Fulda S, Debatin KM: Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 11: 1833-1841, 1997
19. Cheng A, Chuang S, Fine R, Yeh K, Liao C, Lay J, Chen D: Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 55: 523-531, 1998
20. Clark A, West K, Blumberg P, Dennis P: Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res 63: 780-786, 2003
21. Avendano C, Menendez JC: Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 9: 159-193, 2002
22. Fukuda T, Kamishima T, Kakihara T, Ohnishi Y, Suzuki T: Characterization of newly established human myeloid leukemia cell line (KF-19) and its drug resistant sublines. Leuk Res 20: 931-939, 1996
23. Boesch D, Muller K, Pourtier-Manzanedo A, Loor F: Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 196: 26-32, 1991
24. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F: In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51: 4226-4233, 1991
25. Efferth T, Fabry U, Osieka R: Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 11: 1180-1186, 1997
26. Sikic BI: Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology (Huntingt) 13: 183-187, 1999
27. Ogretmen B, Safa AR: Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int J Cancer 67: 608-614, 1996
28. Roninson IB: Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum Press, New York, 1991
29. Sikic BI: Modulation of multidrug resistance: at the threshold. J Clin Oncol 11: 1629-1635, 1993
30. Fisher GA, Sikic BI: Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9: 363-382, 1995
31. Fu J, Chen Z, Cen J, Ruan C: Expression of the human multidrug resistance gene mdrl in leukemic cells and its application in studying P-glycoprotein antagonists. Chin Med J (Engl) 113: 228-231, 2000
32. Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K: Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 25: 771-778, 2002
33. Chadderton A, Villeneuve DJ, Gluck S, Kirwan-rhude AF, Gannon BR, Blais DE, Parissenti AM: Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells. Breast Cancer Res Treat 59: 231-244, 2000
34. Crown J: Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist 6(Suppl 3): 17-21, 2001
35. Kobayashi E, Ando K, Nakano H, Iida T, Ohno H, Morimoto M, Tamaoki T: Calphostins (UCN-1028), novel and specific inhibitors of protein kinase C. I. Fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) 42: 1470-1474, 1989
36. Gupta S, Patel K, Singh H, Gollapudi S: Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein. Cancer Lett 76: 139-145, 1994
37. Dubauskas Z, Beck TP, Chmura SJ, Kovar DA, Kadkhodaian MM, Shrivastav M, Chung T, Stadler WM, Rinker-Schaeffer CW: Activated calphostin C cytotoxicity is independent of p53 status and in vivo metastatic potential. Clin Cancer Res 4: 2391-2398, 1998
38. Beck TP, Kirsh EJ, Chmura SJ, Kovar DA, Chung T, Rinker-Schaeffer CW, Stadler WM: In vitro evaluation of calphostin C as a novel agent for photodynamic therapy of bladder cancer. Urology 54: 573-577, 1999
39. Bates SE, Lee JS, Dickstein B, Spolyar M, Fojo AT: Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry 32: 9156-9164, 1993
40. Matsumoto T, Tani E, Yamaura I, Miyaji K, Kaba K: Effects of protein kinase C modulators on multidrug resistance in human glioma cells. Neurosurgery 36: 565-571, 1995
41. Keating A, Toor P: Human long term bone marrow culture. In: Poclard JM (ed) Wiley Liss, New York, 1990, 331 pp
42. Martin D, Lenardo M: In: Anonymous (ed), Morphological, Biochemical, and Flow cytometric analysis of apoptosis. Wiley, New York, 2000, pp 1-5
43. Saunders DE, Lawrence WD, Christensen C, Wappler NL, Ruan H, Deppe G: Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. Int J Cancer 70: 214-220, 1997
44. Horwitz SB: Mechanism of action of taxol. Trends Pharmacol Sci 13: 134-136, 1992
45. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825, 1996
46. Weitzel DH, Vandre DD: Differential spindle assembly checkpoint response in human lung adenocarcinoma cells. Cell Tissue Res 300: 57-65, 2000
47. Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W: Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 59: 1198-1211, 2002
48. Blajeski AL, Kottke TJ, Kaufmann SH: A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Exp Cell Res 270: 277-288, 2001
49. Serafino A, Sinibaldi-Vallebona P, Pierimarchi P, Bernard P Gaudiano G, Massa C, Rasi G, Ranagnan G: Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering? Anticancer Res 19: 1909-1918, 1999
50. da Silva CP, de Oliveira CR, da Conceicao M, de Lima P: Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. Biochem Pharmacol 51: 1331-1340, 1996
51. Conseil G, Perez-Victoria JM, Jault JM, Gamarro F, Goffeau A, Hofmann J, Di Pietro A: Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. Biochemistry 40: 2564-2571, 2001
52. Robertson AM, Bird CC, Waddell AW, Currie AR: Morphological aspects of glucocorticoid-induced cell death in human lymphoblastoid cells. J Pathol 126: 181-187, 1978
53. Sheridan JW, Bishop CJ, Simmons RJ: Biophysical and morphological correlates of kinetic change and death in a starved human melanoma cell line. J Cell Sci 49: 119-137, 1981
54. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM: Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 274: 5053-5060, 1999
55. Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K: Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 93: 3053-3063, 1999
56. Jordan MA, Toso RJ, Thrower D, Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 9552-9556, 1993
57. Yvon AM, Wadsworth P, Jordan MA: Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10: 947-959, 1999
58. Tarr M, van Helden PD: Inhibition of transcription by adriamycin is a consequence of the loss of negative superhelicity in DNA mediated by topoisomerase II. Mol Cell Biochem 93: 141-146, 1990
59. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ: Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 18: 790, 1998
60. Ueffing M, Lovri J, Philipp A, Mischak H, Kolch W: Protein kinase C Epsilon associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity. Oncogene 15: 2921-2927, 1997
61. Avruch J, Zhang X, Kyriakis J: Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci 19: 279-283, 1994
62. Chapman RS, Whetton AD, Chresta CM, Dive C: Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase. Mol Pharmacol 48: 334-343, 1995
63. Grant S, Jarvis W: Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin Cancer Res 2: 1915-1920, 1996
64. Mayne GC, Murray AW: Evidence that protein kinase Cepsilon mediates phorbol ester inhibition of calphostin C-and tumor necrosis factor-alpha- induced apoptosis in U937 histiocytic lymphoma cells. J Biol Chem 273: 24115-24121, 1998
65. da Rocha AB, Mans DR, Regner A, Schwartsmann G: Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist 7: 17-33, 2002
66. O'Brian CA, Fan D, Ward NE, Seid C, Fidler IJ: Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells. FEBS Lett 246: 78-82, 1989
67. Dong Z, Ward N, Fan D, Gupta K, O'Brian C: In vitro model for intrinsic drug resistance: effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. Mol Pharmacol 39: 563-569, 1991
68. Wilmanns C, Fan D, O'Brian CA, Bucana CD, Fidler IJ: Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 52: 98-104, 1992
69. Chakrabarty S, Huang S: Modulation of chemosensitivity in human colon carcinoma cells by downregulating protein kinase C alpha expression. J Exp Ther Oncol 1: 218-221, 1996
70. Fine RL, Chambers TC, Sachs CW: P-glycoprotein, multidrug resistance and protein kinase C. Oncologist 1: 261-268, 1996
71. Masanek U, Stammler G, Volm M: Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol 2: 37-41, 2002
72. Ikemoto H, Tani E, Matsumoto T, Nakano A, Furuyama J: Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. J Neurosurg 83: 1008-1016, 1995
73. Zhu DM, Narla RK, Fang WH, Chia NC, Uckun FM: Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells. Clin Cancer Res 4: 2967-2976, 1998
74. Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S: Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 54: 1707-1714, 1994
75. Ikemoto H, Tani E, Ozaki I, Kitagawa H, Arita N: Calphostin C-mediated translocation and integration of Bax into mitochondria induces cytochrome c release before mitochondrial dysfunction. Cell Death Differ 7: 511-520, 2000
76. LaRue JM, Stratagoules ED, Martinez JD: Deoxycholic acid-induced apoptosis is switched to necrosis by bcl-2 and calphostin C. Cancer Lett 152: 107-113, 2000
77. Sperandio S, de Belle I, Bredesen DE: An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA 97: 14376-14381, 2000
78. Friedrich K, Wieder T, Von Haefen C, Radetzki S, Janicke R, Schulze-Osthoff K, Dorken B, Daniel PT: Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 20: 2749-2760, 2001
79. Janicke RU, Sprengart ML, Wati MR, Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360, 1998
80. Janicke RU, Ng P, Sprengart ML, Porter AG: Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 273: 15540-15545, 1998
81. Chambers TC, Pohl J, Raynor RL, Kuo JF: Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J Biol Chem 268: 4592-4595, 1993
82. Sachs CW, Chambers TC, Fine RL: Differential phosphorylation of sites in the linker region of P-glycoprotein by protein kinase C isozymes alpha, betaI, betaII, gamma, delta, epsilon, eta, and zeta. Biochem Pharmacol 58: 1587-1592, 1999
83. Chambers T, Chalikonda I, Eilon G: Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells. Biochem Biophys Res Commun 169: 253-259, 1990
84. Hardy SP, Goodfellow HR, Valverde MA, Gill DR, Sepulveda V, Higgins CF: Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. EMBO J 14: 68-75, 1995
85. Goodfellow HR, Sardini A, Ruetz S, Callaghan R, Gros P, McNaughton PA, Higgins CF: Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem 271: 13668-13674, 1996
86. Germann UA, Chambers TC, Ambudkar SV, Licht T, Cardarelli CO, Pastan I, Gottesman MM: Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 271: 1708-1716, 1996
87. Sciorra VA, Hammond SM, Morris AJ: Potent direct inhibition of mammalian phospholipase D isoenzymes by calphostin-C. Biochemistry 40: 2640-2646, 2001
88. Spinedi A, Oliverio S, Di Sano F, Piacentini M: Calpain involvement in calphostin C-induced apoptosis. Biochem Pharmacol 56: 1489-1492, 1998
89. Chmura SJ, Nodzenski E, Weichselbaum RR, Quintans J: Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Cancer Res 56: 2711-2714, 1996
90. Kobayashi E, Nakano H, Morimoto M, Tamaoki T: Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159: 548-553, 1989
91. Tamaoki T, Nakano H: Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology 8: 732-735, 1990
92. Pollack IF, Kawecki S: The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro. J Neurooncol 31: 255-266, 1997
93. Hu DE, Fan TP: Protein kinase C inhibitor calphostin C prevents cytokine-induced angiogenesis in the rat. Inflammation 19: 39-54, 1995
94. Chen CL, Tai HL, Zhu DM, Uckun FM: Pharmacokinetic features and metabolism of calphostin C, a naturally occurring perylenequinone with antileukemic activity. Pharm Res 16: 1003-1009, 1999